Pharma pipelines don’t fail in the lab. They fail in the courtroom.
That’s the uncomfortable truth behind Freedom to Operate (FTO) work—and why the best teams treat it like a strategic discipline, not a one-time legal checkbox.
In a world where patents…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn “Copy” Into Differentiation—and Defense
In generic drug land, the default playbook is simple: file an ANDA, win on price, and let the market do the rest.
But that playbook is increasingly crowded—and …

Pharma IP teams are used to playing offense—filing early, building families, tightening claim scope, and mapping exclusivity like a chessboard. But right now, Russia’s patent-term extension landscape is a reminder that the “defensive” playbook matters …

Drug patent portfolios shouldn’t just sit on the shelf—they should be engineered to win.
In pharma, the default playbook is often “file early, hope for the best, and defend later.” But the market has changed. Litigation is no longer a rare event; it’…

Hospitals are sitting on a quiet competitive advantage—and many are ignoring it.
In the pharmaceutical supply chain, “patent expiration” is often treated like a distant calendar event. But for hospital systems, it’s not a trivia question. It’s a procur…

Generic launches don’t “just happen.” They’re engineered by time, law, and leverage.
If you’re still forecasting generic drug launch dates using spreadsheets and historical averages, you’re already behind. In today’s patent landscape—where exclusivit…

The FDA Orange Book isn’t just a database—it’s a talent map.
Most people treat the Orange Book like a compliance tool: a place to confirm patents, check exclusivity, and move on. But if you’re in business development, licensing, or competitive intellig…

Biotech investors love “pipeline value,” but most portfolio rankings still miss the point: value is not just what you own—it’s what you can recover from it, and how quickly.
That’s where two unglamorous finance tools—Net Present Value (NPV) and the Pro…

The “patent cliff” isn’t just a pharma problem—it’s a talent problem.
When blockbuster drugs lose exclusivity, the headlines focus on revenue, pricing pressure, and pipeline triage. But there’s another cliff that rarely gets discussed: the talent cliff…

Overstocking branded drugs isn’t just a balance-sheet problem—it’s a patent-timing problem.
For wholesalers, the risk isn’t theoretical. It shows up as expensive inventory that can’t be sold at the expected margin, write-downs that hit quarterly earnin…